CKPT SHAREHOLDER ALERT: TOP RANKED ROSEN LAW FIRM Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important June 4 Deadline in Securities Class Action – CKPT
23 mai 2024 12h38 HE
|
The Rosen Law Firm PA
NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March...
Hyloris Pharmaceuticals Elargit son Portefeuille de Produits avec un Spray Nasal pour la Rhinite Idiopathique
22 nov. 2022 12h00 HE
|
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals Elargit son Portefeuille de Produits avec un Produit Candidat Intranasal Propriétaire d'un Agoniste TRPV11 (HY-083) pour la Rhinite Idiopathique - Hyloris cible une...
Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
22 nov. 2022 12h00 HE
|
Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals Broadens Pipeline with a Proprietary Intranasal Product Candidate of a TRPV11 agonist (HY-083) for Idiopathic Rhinitis Hyloris targets a condition that affects up to 7% of...
Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
11 juil. 2019 17h28 HE
|
Ritter Pharmaceuticals, Inc.
Ritter Shares Will Continue to Trade on the Nasdaq Capital Market LOS ANGELES, July 11, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the...